Stocks and Investing
Stocks and Investing
Tue, November 9, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, November 8, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Downgraded (BLUE) to Sell and Held Target at $11 on, Nov 8th, 2021
Matthew Harrison of Morgan Stanley, Downgraded "bluebird bio, Inc." (BLUE) to Sell and Held Target at $11 on, Nov 8th, 2021.
Matthew has made no other calls on BLUE in the last 4 months.
There are 3 other peers that have a rating on BLUE. Out of the 3 peers that are also analyzing BLUE, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- John Newman of "Canaccord Genuity" Downgraded from Strong Buy to Hold and Decreased Target to $20 on, Tuesday, August 10th, 2021
- Yanan Zhu of "Wells Fargo" Downgraded from Buy to Hold and Decreased Target to $25 on, Tuesday, August 10th, 2021
This is the rating of the analyst that currently disagrees with Matthew
- Difei Yang of "Mizuho" Maintained at Strong Buy with Decreased Target to $23 on, Wednesday, September 22nd, 2021
Contributing Sources